Effectiveness of genetic cascade screening for familial hypercholesterolaemia using a centrally co-ordinated clinical service: An Australian experience

Atherosclerosis

Volumn 239, Issue 1, 2015, Pages 93-100

  Bell, Damon A ^a,b   Pang, Jing ^b   Burrows, Sally ^b   Bates, Timothy R ^a,b   van Bockxmeer, Frank M ^a,c   Hooper, Amanda J ^a,b,c   O'Leary, Peter ^d,e,f   Burnett, John R ^a,b   Watts, Gerald F ^a,b  

^a ROYAL PERTH HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d CURTIN UNIVERSITY   (Australia)

^e UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^f PATHWEST LABORATORY MEDICINE   (Australia)

Author keywords

Cascade screening; Effectiveness; Familial hypercholesterolaemia; Genes; Yield

Indexed keywords

APOLIPOPROTEIN B; ATORVASTATIN; CHOLESTEROL; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; PRAVASTATIN; ROSUVASTATIN; TRIACYLGLYCEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ARTICLE; AUSTRALIA; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; GENETIC CASCADE SCREENING; GENETIC SCREENING; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SMOKING; TRIACYLGLYCEROL BLOOD LEVEL; AGED; BLOOD; CARDIOLOGY; FAMILY HEALTH; GENETICS; HYPERLIPOPROTEINEMIA TYPE II; MIDDLE AGED; MUTATION; ORGANIZATION AND MANAGEMENT; PROCEDURES; RISK FACTOR;

ADULT; AGED; AUSTRALIA; CARDIOLOGY; CHOLESTEROL, LDL; FAMILY HEALTH; FEMALE; GENETIC TESTING; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIA TYPE II; MALE; MIDDLE AGED; MUTATION; RISK FACTORS;

EID: 84920748229     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.12.036     Document Type: Article

References (61)

1. Wilson J.M., Jungner Y.G. Principles and Practice of Mass Screening for Disease 1968, World Health Organization, Geneva.
2. Watts G.F., et al. Familial hypercholesterolaemia: a model of care for Australasia. Atheroscler. Suppl. 2011, 12(2):221-231.
3. Bender R., et al. Screening for familial hypercholesterolaemia. Pathology 2012, 44(2):122-128.
4. Nordestgaard B.G., et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur. Heart J. 2013, 34(45):3478-3490.
5. Marks D., et al. Areview on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis 2003, 168(1):1-14.
6. Huijgen R., et al. Discriminative ability of LDL-cholesterol to identify patients with familial hypercholesterolemia: a cross-sectional study in 26,406 individuals tested for genetic FH. Circ. Cardiovasc. Genet. 2012, 5(3):354-359.
7. World Health Organisation Familial Hypercholesterolaemia (FH): Report of a Second WHO Consultation. Geneva 1999.
8. Scientific Steering Committee of behalf of Simon Broome Register Group Risk of fatal coronary heart disease in familial hypercholesterolaemia. BMJ 1991, 303:893-896.
9. Williams R., Hunt S., Schumacher M. Diagnosing heterozygous familial hypercholesterolaemia using new practical criteria validated by molecular genetics. Am. J. Cardiol. 1993, 72:171-176.
10. Harada-Shiba M., et al. Multicenter study to determine the diagnosis criteria of heterozygous familial hypercholesterolemia in Japan. J.Atheroscler. Thromb. 2012, 19(11):1019-1026.
11. Austin M.A., et al. Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review. Am. J. Epidemiol. 2004, 160(5):407-420.
12. Soutar A.K., Naoumova R.P. Mechanisms of disease: genetic causes of familial hypercholesterolemia. Nat. Clin. Pract. Cardiovasc. Med. 2007, 4(4):214-225.
13. Hooper A.J., et al. Genetic analysis of familial hypercholesterolaemia in Western Australia. Atherosclerosis 2012, 224(2):430-434.
14. Descamps O.S., et al. Management of familial hypercholesterolemia in children and young adults: consensus paper developed by a panel of lipidologists, cardiologists, paediatricians, nutritionists, gastroenterologists, general practitioners and a patient organization. Atherosclerosis 2011, 218(2):272-280.
15. Daniels S.R., et al. Pediatric aspects of familial hypercholesterolemias: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J.Clin. Lipidol. 2011, 5(3 Suppl.l):S30-S37.
16. Watts G.F., et al. Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. Int. J. Cardiol. 2014, 171(3):309-325.
17. Ademi Z., et al. Cascade screening based on genetic testing is cost-effective: evidence for the implementation of models of care for familial hypercholesterolemia. J.Clin. Lipidol. 2014, 8(4):390-400.
18. National Institute for Health and Clinical Excellence and The National Collaborating Centre for Primary Care NICE Clinical Guideline 71: Identification and Management of Familial Hypercholesterolaemia 2008, Available from:. http://www.nice.org.uk/nicemedia/pdf/CG071NICEGuideline.pdf.
19. Umans-Eckenhausen M.A., et al. Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands. Lancet 2001, 357(9251):165-168.
20. Bhatnagar D., Morgan J., Siddiq S. Outcome of case finding among relatives of patients with known heterozygous familial hypercholesterolaemia. BMJ 2000, 321:1497-1500.
21. Versmissen J., et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ 2008, 337:a2423.
22. Baigent C., et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010, 376(9753):1670-1681.
23. Benn M., et al. Familial hypercholesterolemia in the Danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. J.Clin. Endocrinol. Metabol. 2012, 97(11):3956-3964.
24. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 1972, 18(6):499-502.
25. Neil A., et al. Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. Eur. Heart J. 2008, 29(21):2625-2633.
26. Leren T.P., et al. Application of molecular genetics for diagnosing familial hypercholesterolemia in Norway: results from a family-based screening program. Semin. Vasc. Med. 2004, 4(1):75-85.
27. Muir L.A., et al. Preventing cardiovascular disease: a review of the effectiveness of identifying the people with familial hypercholesterolaemia in New Zealand. N.Z. Med. J. 2010, 123(1326):97-102.
28. Bourbon M., et al. Familial hypercholesterolaemia in Portugal. Atherosclerosis 2008, 196(2):633-642.
29. Morris J.K., Wald D.S., Wald N.J. The evaluation of cascade testing for familial hypercholesterolemia. Am. J. Med. Genet. A 2012, 158A(1):78-84.
30. Jannes C.E., et al. Familial hypercholesterolemia in Brazil: cascade screening program, clinical and genetic aspects. Atherosclerosis 2014, 238(1):101-107.
31. Marks D., et al. Cost effectiveness analysis of different approaches of screening for familial hypercholesterolaemia. BMJ 2002, 324(7349):1303.
32. Watts G.F., et al. Familial hypercholesterolaemia: a review with emphasis on evidence for treatment, new models of care and health economic evaluations. Int. J. Evid. Based Healthc. 2012, 10(3):211-221.
33. Ademi Z., et al. Asystematic review of economic evaluations of the detection and treatment of familial hypercholesterolemia. Int. J. Cardiol. 2013, 167:2391-2396.
34. Hardcastle S.J., et al. Patients' perceptions and experiences of familial hypercholesterolemia, cascade genetic screening and treatment. Int. J. Behav. Med. 2014, 1-9.
35. Marks D., et al. Cascade screening for familial hypercholesterolaemia: implications of a pilot study for national screening programmes. J.Med. Screen. 2006, 13:156-159.
36. Hadfield S.G., et al. Family tracing to identify patients with familial hypercholesterolaemia: the second audit of the Department of Health Familial Hypercholesterolaemia Cascade Testing Project. Ann. Clin. Biochem. 2009, 46(Pt 1):24-32.
37. Hu M., et al. Heterozygous familial hypercholesterolemia in Hong Kong Chinese. Study of 252 cases. Int. J. Cardiol. 2013, 167(3):762-767.
38. Taylor A., et al. Mutation detection rate and spectrum in familial hypercholesterolaemia patients in the UK pilot cascade project. Clin. Genet. 2010, 77(6):572-580.
39. Marduel M., et al. Molecular spectrum of autosomal dominant hypercholesterolemia in France. Hum. Mutat. 2010, 31(11):E1811-E1824.
40. Medeiros A.M., et al. Update of the Portuguese familial hypercholesterolaemia study. Atherosclerosis 2010, 212(2):553-558.
41. Reiner Ž., et al. ESC/EAS guidelines for the management of dyslipidaemias. Eur. Heart J. 2011, 32(14):1769-1818.
42. Stone N.J., et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014, 129(25 Suppl.2):S1-S45.
43. Bell D.A., et al. Familial hypercholesterolaemia in primary care: knowledge and practices among general practitioners in western Australia. Heart Lung Circ. 2014, 23(4):309-313.
44. Foody J.M. Familial hypercholesterolemia: an under-recognized but significant concern in cardiology practice. Clin. Cardiol. 2014, 37(2):119-125.
45. Bell D.A., Watts G.F. Response to familial hypercholesterolemia: an under-recognized but significant concern in cardiology practice. Clin. Cardiol. 2014, 37(6):386-387. J.M. Foody etal.
46. Huijgen R., et al. Two years after molecular diagnosis of familial hypercholesterolemia: majority on cholesterol-lowering treatment but a minority reaches treatment goal. PLoS One 2010, 5(2):e9220.
47. Pijlman A.H., et al. Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands. Atherosclerosis 2010, 209(1):189-194.
48. Couture P., et al. Association of specific LDL receptor gene mutations with differential plasma lipoprotein response to simvastatin in young French Canadians with heterozygous familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 1998, 18(6):1007-1012.
49. Miltiadous G., et al. Genetic and environmental factors affecting the response to statin therapy in patients with molecularly defined familial hypercholesterolaemia. Pharm. Genomics 2005, 15(4):219-225.
50. NICE Clinical Guideline 71: Identification and Management of Familial Hypercholesterolaemia 2008, Available from:. http://www.nice.org.uk/nicemedia/pdf/CG071NICEGuideline.pdf.
51. Goldberg A.C., et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J.Clin. Lipidol. 2011, 5(3):133-140.
52. Ganga H.V., Slim H.B., Thompson P.D. Asystematic review of statin-induced muscle problems in clinical trials. Am. Heart J. 2014, 168(1):6-15.
53. Rosenson R.S., et al. An assessment by the Statin Muscle Safety Task Force: 2014 update. J.Clin. Lipidol. 2014, 8(3 Suppl.l):S58-S71.
54. Heart UK F.S.l., Saving Families. The Health, Social and Economic Advantages of Detecting and Treating Familial Hypercholesterolaemia (FH) 2012, http://heartuk.org.uk/files/uploads/documents/HUK_SavingLivesSavingFamilies_FHreport_Feb2012.pdf.
55. Raal F.J., et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet 2014, 10.1016/S0140-6736(14)61399-4.
56. Chapman M.J., et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur. Heart J. 2011, 32(11):1345-1361.
57. Alonso R., et al. Cardiovascular disease in familial hypercholesterolaemia: influence of low-density lipoprotein receptor mutation type and classic risk factors. Atherosclerosis 2008, 200(2):315-321.
58. Jansen A.C.M., et al. The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients. J.Intern. Med. 2004, 256(6):482-490.
59. Harada-Shiba M., et al. Guidelines for the management of familial hypercholesterolemia. J.Atheroscler. Thromb. 2012, 19(12):1043-1060.
60. Nordestgaard B.G., et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur. Heart J. 2010, 31(23):2844-2853.
61. Vickery A.W., et al. Optimising the detection and management of familial hypercholesterolaemia: central role of primary care and its integration with specialist services. Heart Lung Circ. 2014, 23(12):1158-1164.